Lawsuit filed for Investors who lost money with shares of Agenus Inc. (NASDAQ: AGEN)

An investor, who purchased shares of Agenus Inc. (NASDAQ: AGEN), filed a lawsuit over alleged violations of Federal Securities Laws by Agenus Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Agenus Inc. (NASDAQ: AGEN) have certain options and for certain investors are short and strict deadlines running. Deadline: November 5, 2024. NASDAQ: AGEN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Lexington, MA based Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. Among other product candidates, the Company is developing balstilimab, an anti-PD-1 antagonist that has completed a Phase 2 clinical trial to treat second line cervical cancer; and botensilimab, an antigen 4 blocking antibody that is in a Phase 2 clinical trial for the treatment of pancreatic cancer and melanoma.

On July 18, 2024, Agenus Inc. (NASDAQ: AGEN) announced the results of an "end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM)." The press release revealed that the "FDA advised against submission of these results in support of an Accelerated Approval based on their view that objective response rates may not translate to survival benefit."

Shares of Agenus Inc. (NASDAQ: AGEN) declined from $19.69 per share on June 04, 2024, to as low as $4.41 per share on August 14, 2024.

The plaintiff claims that between January 23, 2023 and July 17, 2024, the Defendants made false and/or misleading statements and/or failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe, that accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Agenus Inc. (NASDAQ: AGEN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.